CompuGroup Medical confirms mid-term ambition at the Capital Markets Day

• CGM well on track for strong revenue growth in 2022
• Mid-term organic revenue growth of more than 5 % CAGR reconfirmed
• Adjusted EBITDA Margin improvement post investment phase towards 27 % by 2025
• Every segment delivers on revenue growth and margin expansion
• Recently raised guidance for 2022 confirmed

Koblenz. CompuGroup Medical SE & Co. KGaA (CGM), one of the world’s leading e-health providers, today holds its Capital Markets Day 2022 in Koblenz. The Managing Directors and the CGM US CEO give deep insights into the growth opportunities of every segment and how the company’s product offering supports the ongoing digitization in healthcare. 

The company communicated mid-term targets at the prior year’s Capital Markets Day in September 2021 for the first time. During the past twelve months, CGM delivered on those targets, and management confirms the ambition to organically grow at an average annual compound growth rate of 5 percent and more from 2021 to 2025 and to increase the adjusted EBITDA margin to approximately 25 % in 2023 and to approximately 27 % in 2025. The share of recurring revenue, which underlines the high resilience of CGM’s business, is expected to increase to more than 70 % in 2025.

“With the comprehensive product portfolio, CGM is ideally positioned to support all healthcare practitioners with the changing requirements in the healthcare sector. The digital patient journey is becoming reality and we provide all building blocks for the needs of our customers”, says the Spokesman for the Managing Directors & CFO Michael Rauch “Every segment is committed to deliver increased returns from the investments initiated in 2021 with Q4-2022 being the first proof point.” 

Further information on the Capital Markets Day 2022 are available for download on the company website under Investor Relations.